65,437 trials
Hernia, Abdominal · Abdominal Injuries
Primary: Number of Participants With Hernia Recurrence or Undergo Reoperation for Hernia at 36 Months Post-surgery — 19; 66; 12; 73 Participants
Anesthesia, General
Primary: Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 82.08; 3.95; 2.48; 2.17 Minutes
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Scores — -38.8; -34.0; -32.2; -31.07 units on a scale — p==0.428
Renal Impairment
Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 64.5; 45.1 μM•hr
Acute Myeloid Leukemia
Primary: Leukemia-Free Survival — 6.7; 17.6; 13.9 MONTHS
HIV/AIDS · Housing Problems
Primary: Number of Participants With Placement in Permanent Housing — 53; 37 Participants
Diabetic Kidney Disease
Primary: MCP-1:Creatinine Ratio in Urine — 27.9; 24.3 ng/mmol
Myopia
Primary: Comfort — 83; 77; 83; 83 units on a scale
Tobacco Dependence
Primary: Plasma Cotinine Concentration — 82.8; 259.0 ng/mL — p=<0.0001
Nephrotic Syndrome
Primary: Remission Rate — 34; 13 Participants — p=0.001
Heart Failure
Primary: 6 Minute Walk Test — 224; 247 meters
Renal Insufficiency, Chronic · Kidney Disease, Chronic
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
NK/T-cell Lymphoma of Nasal Cavity
Primary: Compete Response Rate — 31 participants
Rheumatoid Arthritis
Primary: Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months — -4.3; -3.4; -5.6; -6.7 days
Smoking Cessation
Primary: Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 22.9; 30.8 ng/mL